Polly Clayden - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Polly Clayden

Showing results (21-30 of 23) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 23 results.

The Lancet. HIV|December 4, 2018

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling studyAndrew N Phillips, Francois Venter, Diane Havlir, et al.

The Lancet. HIV|August 19, 2024

The long wait for long-acting HIV prevention and treatment formulationsWillem Daniel Francois Venter, Monica Gandhi, Simiso Sokhela, et al.

Open Forum Infectious Diseases|March 26, 2024

Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral RegimensSimiso Sokhela, Willem D F Venter, Bronwyn Bosch, et al.

Pageof 3

Search research articles

Showing results (21-30 of 23) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 23 results.

The Lancet. HIV|December 4, 2018

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling studyAndrew N Phillips, Francois Venter, Diane Havlir, et al.

The Lancet. HIV|August 19, 2024

The long wait for long-acting HIV prevention and treatment formulationsWillem Daniel Francois Venter, Monica Gandhi, Simiso Sokhela, et al.

Open Forum Infectious Diseases|March 26, 2024

Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral RegimensSimiso Sokhela, Willem D F Venter, Bronwyn Bosch, et al.

Pageof 3